Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer

Kyong Joo Lee, Hee Man Kim, Joo Won Jung, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Woo Jung Lee, Jin Sil Seong, Si Young Song

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6%) and hemorrhage (25.6%), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65%). The origins of GI hemorrhage were gastric ulcer (37.5%), duodenal ulcer (37.5%), and radiation gastritis (15.0%). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalGut and liver
Volume7
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Gastrointestinal Hemorrhage
Chemoradiotherapy
Pancreatic Neoplasms
Endoscopic Hemostasis
Hemorrhage
Survival
Gastritis
Stomach Ulcer
Duodenal Ulcer
Psychological Stress
Ulcer
Medical Records
Radiation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Lee, Kyong Joo ; Kim, Hee Man ; Jung, Joo Won ; Chung, Moon Jae ; Park, Jeong Youp ; Bang, Seungmin ; Park, Seung Woo ; Lee, Woo Jung ; Seong, Jin Sil ; Song, Si Young. / Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer. In: Gut and liver. 2013 ; Vol. 7, No. 1. pp. 106-111.
@article{7132cb3e35be400dbe3077fe3e9ba406,
title = "Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer",
abstract = "Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6{\%}) and hemorrhage (25.6{\%}), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65{\%}). The origins of GI hemorrhage were gastric ulcer (37.5{\%}), duodenal ulcer (37.5{\%}), and radiation gastritis (15.0{\%}). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering.",
author = "Lee, {Kyong Joo} and Kim, {Hee Man} and Jung, {Joo Won} and Chung, {Moon Jae} and Park, {Jeong Youp} and Seungmin Bang and Park, {Seung Woo} and Lee, {Woo Jung} and Seong, {Jin Sil} and Song, {Si Young}",
year = "2013",
month = "1",
day = "1",
doi = "10.5009/gnl.2013.7.1.106",
language = "English",
volume = "7",
pages = "106--111",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

Lee, KJ, Kim, HM, Jung, JW, Chung, MJ, Park, JY, Bang, S, Park, SW, Lee, WJ, Seong, JS & Song, SY 2013, 'Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer', Gut and liver, vol. 7, no. 1, pp. 106-111. https://doi.org/10.5009/gnl.2013.7.1.106

Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer. / Lee, Kyong Joo; Kim, Hee Man; Jung, Joo Won; Chung, Moon Jae; Park, Jeong Youp; Bang, Seungmin; Park, Seung Woo; Lee, Woo Jung; Seong, Jin Sil; Song, Si Young.

In: Gut and liver, Vol. 7, No. 1, 01.01.2013, p. 106-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gastrointestinal hemorrhage after concurrent chemoradiotherapy in locally advanced pancreatic cancer

AU - Lee, Kyong Joo

AU - Kim, Hee Man

AU - Jung, Joo Won

AU - Chung, Moon Jae

AU - Park, Jeong Youp

AU - Bang, Seungmin

AU - Park, Seung Woo

AU - Lee, Woo Jung

AU - Seong, Jin Sil

AU - Song, Si Young

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6%) and hemorrhage (25.6%), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65%). The origins of GI hemorrhage were gastric ulcer (37.5%), duodenal ulcer (37.5%), and radiation gastritis (15.0%). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering.

AB - Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6%) and hemorrhage (25.6%), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65%). The origins of GI hemorrhage were gastric ulcer (37.5%), duodenal ulcer (37.5%), and radiation gastritis (15.0%). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering.

UR - http://www.scopus.com/inward/record.url?scp=84875088236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875088236&partnerID=8YFLogxK

U2 - 10.5009/gnl.2013.7.1.106

DO - 10.5009/gnl.2013.7.1.106

M3 - Article

C2 - 23423146

AN - SCOPUS:84875088236

VL - 7

SP - 106

EP - 111

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -